INSM - Insmed Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.07
-0.27 (-1.65%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.34
Open16.21
Bid0.00 x 1300
Ask0.00 x 800
Day's Range15.96 - 16.62
52 Week Range11.31 - 33.13
Volume603,475
Avg. Volume1,194,411
Market Cap1.42B
Beta (3Y Monthly)3.44
PE Ratio (TTM)N/A
EPS (TTM)-4.09
Earnings DateOct 28, 2019 - Nov 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.13
Trade prices are not sourced from all markets
  • Volatility 101: Should Insmed (NASDAQ:INSM) Shares Have Dropped 28%?
    Simply Wall St.

    Volatility 101: Should Insmed (NASDAQ:INSM) Shares Have Dropped 28%?

    The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...

  • Thomson Reuters StreetEvents

    Edited Transcript of INSM earnings conference call or presentation 1-Aug-19 12:30pm GMT

    Q2 2019 Insmed Inc Earnings Call

  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Aug. 2, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to five new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on August 1, 2019 to purchase an aggregate 17,110 shares of Insmed common stock at an exercise price of $19.24 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

  • Insmed (INSM) Q2 2019 Earnings Call Transcript
    Motley Fool

    Insmed (INSM) Q2 2019 Earnings Call Transcript

    INSM earnings call for the period ending June 30, 2019.

  • Here’s Why Insmed Fell Hard Today
    Motley Fool

    Here’s Why Insmed Fell Hard Today

    After a solid second quarter, investors in the biopharmaceutical company were left to wonder about management’s tepid growth forecast.

  • Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

    Insmed (INSM) delivered earnings and revenue surprises of 4.71% and 20.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Insmed Reports Second Quarter 2019 Financial Results and Provides Business Update
    PR Newswire

    Insmed Reports Second Quarter 2019 Financial Results and Provides Business Update

    --ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $29.0 Million for the Second Quarter of 2019-- --Marketing Authorization Application for ARIKAYCE Submitted and Validated by ...

  • Insmed to Host Second Quarter 2019 Financial Results Conference Call on Thursday, August 1, 2019
    PR Newswire

    Insmed to Host Second Quarter 2019 Financial Results Conference Call on Thursday, August 1, 2019

    BRIDGEWATER, N.J. , July 25, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today ...

  • Insmed Announces Closing of Public Offering of Common Stock
    PR Newswire

    Insmed Announces Closing of Public Offering of Common Stock

    BRIDGEWATER, N.J., June 26, 2019 /PRNewswire/ -- Insmed Incorporated (INSM) today announced the closing on June 25, 2019 of the issuance of an additional 1,442,307 shares of common stock pursuant to the full exercise of the underwriter's overallotment option related to the previously announced public offering of its common stock. The underwriters were granted 30-day options to purchase up to an additional 1,042,307 shares of common stock from Insmed and up to 400,000 shares of common stock from William H. Lewis, the Company's Chairman and Chief Executive Officer at a public offering price of $26.00 per share. The net proceeds to the Company from the sale of the additional shares, after deducting underwriting discounts and commissions but before expenses, were approximately $25.6 million.  The Company did not receive any proceeds from the sale of Mr. Lewis' shares.

  • GuruFocus.com

    Insmed Inc (INSM) Chairman, President & CEO William Lewis Sold $10.4 million of Shares

    Chairman, President & CEO of Insmed Inc (NASDAQ:INSM) William Lewis sold 400,000 shares of INSM on 06/25/2019 at an average price of $26 a share.

  • Markit

    See what the IHS Markit Score report has to say about Insmed Inc.

    Insmed Inc NASDAQ/NGS:INSMView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for INSM with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 11. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding INSM are favorable, with net inflows of $2.18 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Insmed Incorporated (INSM) A Good Stock To Buy?
    Insider Monkey

    Is Insmed Incorporated (INSM) A Good Stock To Buy?

    Is Insmed Incorporated (NASDAQ:INSM) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]

  • Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
    PR Newswire

    Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

    BRIDGEWATER, N.J., June 6, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Palos Verdes on Thursday, June 13, 2019 at 8:00 a.m. PDT. Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.

  • Thomson Reuters StreetEvents

    Edited Transcript of INSM earnings conference call or presentation 7-May-19 12:30pm GMT

    Q1 2019 Insmed Inc Earnings Call

  • What Did Insmed Incorporated's (NASDAQ:INSM) CEO Take Home Last Year?
    Simply Wall St.

    What Did Insmed Incorporated's (NASDAQ:INSM) CEO Take Home Last Year?

    In 2012 Will Lewis was appointed CEO of Insmed Incorporated (NASDAQ:INSM). This report will, first, examine the CEO...

  • Benzinga

    The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...

  • Insmed Announces Pricing of Public Offering of Common Stock
    PR Newswire

    Insmed Announces Pricing of Public Offering of Common Stock

    BRIDGEWATER, N.J., May 21, 2019 /PRNewswire/ -- Insmed Incorporated (INSM) announced today that it priced a registered underwritten public offering of 9,615,385 shares of its common stock, at a price to the public of $26.00 per share before underwriting discounts and commissions. Gross proceeds from the offering of these shares, before deducting underwriting discounts and commissions, are expected to be approximately $250.0 million.  The underwriters have been granted 30-day options to purchase up to an additional 1,042,307 shares of common stock from Insmed and up to 400,000 shares of common stock from William H. Lewis, the Company's Chairman and Chief Executive Officer.

  • Benzinga

    The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 20) Kaleido Biosciences Inc (NASDAQ: KLDO ) Down In The ...

  • Insmed Announces Proposed Public Offering of Common Stock
    PR Newswire

    Insmed Announces Proposed Public Offering of Common Stock

    BRIDGEWATER, N.J., May 20, 2019 /PRNewswire/ -- Insmed Incorporated (INSM) announced today that it has commenced an underwritten public offering of up to $250 million of its common stock. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional $25.5 million of its common stock at the public offering price, less the underwriting discounts and commissions. William H. Lewis, the Company's Chairman and Chief Executive Officer, intends to grant the underwriters a 30-day option to purchase up to $12 million of Insmed common stock held by Mr. Lewis also at the public offering price.

  • New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease
    PR Newswire

    New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease

    BRIDGEWATER, N.J., May 20, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today presented new data from the ongoing Phase 3 CONVERT study of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with refractory Mycobacterium avium complex (MAC) lung disease, demonstrating that the addition of ARIKAYCE to guideline-based therapy (GBT) was associated with sustained culture conversion through the end of treatment as well as durable culture conversion three months post-treatment compared with GBT alone.

  • Insmed (INSM) Q1 2019 Earnings Call Transcript
    Motley Fool

    Insmed (INSM) Q1 2019 Earnings Call Transcript

    INSM earnings call for the period ending March 31, 2019.